Search
Search Results
-
Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study
BackgroundIn addition to decreasing the level of cholesterol, proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has pleiotropic effects,...
-
Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviates atherosclerosis progression
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors have been shown to regulate lipid metabolism and reduce the risk of cardiovascular...
-
Lipids
Hyperlipidemia is a common medical condition encountered in the ambulatory setting. It is one of the risk factors for cardiovascular disease....
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference
Purpose of ReviewTo summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2024 Scientific Session of...
-
PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
Purpose of ReviewTreatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV)...
-
Triticum aestivum Octacosanol, a Potential Inhibitor of PCSK9 in Fat Diet–Induced Hypercholesteromia
Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a circulating serine protease that promotes the degradation of low-density lipoprotein...
-
Longitudinal variation of serum PCSK9 in ulcerative colitis: association with disease activity, T helper 1/2/17 cells, and clinical response of tumor necrosis factor inhibitor
AimsProprotein convertase subtilisin/kexin type 9 (PCSK9) modulates CD4 + T cell differentiation and inflammatory response, the latter ones mediate...
-
Hyperlipoproteinämien [E78.-]
Das VorhandenseinHyperlipoproteinämie einer Dyslipidämie ist assoziiert mit einem erhöhten Risiko, ein (tödliches oder nicht-tödliches)...
-
Drugs Used in Dyslipidemia
Nearly one-third of death worldwide can be attributed to cardiovascular disease (CVD) and 24.8% of all death in India is attributed to CVD....
-
-
Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I:C)-stimulated macrophages
Macrophages plasticity is a key feature in cancer progression. Neoplastic cells can alter their immune functions and orient them into a pro-tumoral...
-
Vascular leak in sepsis: physiological basis and potential therapeutic advances
Sepsis is a life-threatening condition characterised by endothelial barrier dysfunction and impairment of normal microcirculatory function, resulting...
-
Artificial Neural Network-Based Study Predicts GS-441524 as a Potential Inhibitor of SARS-CoV-2 Activator Protein Furin: a Polypharmacology Approach
Furin, a pro-protein convertase, plays a significant role as a biological scissor in bacterial, viral, and even mammalian substrates which in turn...
-
Lipoprotein (a) [Lp(a)]
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for the development of atherosclerotic cardiovascular disease (ASCVD)-related events...
-
Strategies for chronic coronary disease: A brief guide for clinicians
The 2023 Multisociety Guidelines for the Management of Patients with Chronic Coronary Disease (CCD) is a collaborative effort between the American...
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
ObjectiveThere is a large population of patients classified as complex higher-risk and indicated patients (CHIPs) in China with a poor prognosis. The...
-
Outpatient Management of Coronary Artery Disease
Patients with coronary artery related chest pain have a wide range of chronic pathologies. They may have a history of single vessel disease which was...
-
Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention
BackgroundCurrent guidelines recommend a stepwise initiation of lipid-lowering therapy after percutaneous coronary interventions (PCI) in...
-
The Interaction Between Infection, Crystals, and Cardiovascular Disease
This chapter highlights the potential interplay between infection, crystals, and cardiovascular diseases. Specifically, it examines how cholesterol...